Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following are examples of physiological antagonism?

Both B and C. ### Explanation **Concept of Physiological Antagonism** Physiological (or functional) antagonism occurs when two drugs act on **different receptors** and produce **opposing physiological effects** on the same effector organ or system. Unlike pharmacological antagonism, they do not compete for the same receptor site. **Why Option D (Both B and C) is Correct:** * **Adrenaline and Histamine (Option B):** This is the classic textbook example. Histamine acts on **H₁ receptors** causing bronchoconstriction and vasodilation. Adrenaline acts on **β₂ receptors** (bronchodilation) and **α₁ receptors** (vasoconstriction). Because they produce opposite effects via different receptors, adrenaline is the physiological antagonist of histamine and is the drug of choice for anaphylactic shock. * **Salbutamol and Leukotrienes (Option C):** Leukotrienes (e.g., LTC4, LTD4) act on **CysLT₁ receptors** to cause potent bronchoconstriction. Salbutamol acts on **β₂ receptors** to cause bronchodilation. Since they act on different receptors to produce opposite effects on bronchial smooth muscle, they are physiological antagonists. **Why Option A is Incorrect:** * **Adrenaline and Salbutamol:** Both drugs are **agonists** at the β₂-adrenergic receptor. They produce synergistic (additive) effects on bronchodilation rather than opposing each other. **NEET-PG High-Yield Pearls:** * **Chemical Antagonism:** Occurs when two drugs react chemically in solution (e.g., Heparin and Protamine sulfate; Chelating agents and heavy metals). * **Pharmacological Antagonism:** Occurs at the same receptor (e.g., Atropine and Acetylcholine at Muscarinic receptors). * **Clinical Application:** Adrenaline is used in anaphylaxis because it works instantly via physiological antagonism, bypassing the histamine receptor blockade which would be too slow.

Q: In competitive antagonism, what happens to the Vmax?

Vmax remains the same. In **competitive antagonism**, the antagonist binds reversibly to the same active site as the agonist. Because they compete for the same receptor, the outcome depends on the relative concentrations of the two molecules. ### Why the correct answer is right: * **Vmax (Efficacy) remains the same:** If you increase the concentration of the agonist sufficiently, it can "outcompete" and displace the antagonist from the receptors. Therefore, the maximal response (Vmax or Emax) can still be achieved, provided enough agonist is present. On a graph, this is represented by a **parallel rightward shift** of the dose-response curve. ### Why the incorrect options are wrong: * **Potency remains the same:** This is incorrect. Because more agonist is required to achieve the same effect in the presence of an antagonist, the **EC50 increases**, meaning the **potency decreases**. * **Km decreases:** In enzyme kinetics (analogous to receptor binding), competitive inhibition **increases the Km** (Michaelis constant). A higher Km indicates a decreased affinity of the enzyme/receptor for the substrate/agonist. * **Efficacy decreases:** This is a characteristic of **non-competitive antagonism**, where the antagonist binds to an allosteric site or binds irreversibly, preventing the agonist from reaching Vmax regardless of the dose. ### High-Yield Clinical Pearls for NEET-PG: * **Competitive Antagonism:** Parallel rightward shift, Vmax constant, Km/EC50 increases. (Example: Atropine vs. Acetylcholine). * **Non-Competitive Antagonism:** Downward shift, Vmax decreases, Km/EC50 remains constant. (Example: Phenoxybenzamine at alpha receptors). * **Key Distinction:** Competitive antagonism can be overcome by increasing agonist concentration; non-competitive cannot.

Q: Which route of administration will produce the least onset of action?

Application to a bronchotracheal mucous membrane. ### Explanation The speed of onset of action for any drug is primarily determined by the **vascularity** of the site of administration and the **surface area** available for absorption. **Why Option C is Correct:** The **bronchotracheal mucous membrane** has a relatively smaller surface area and lower vascular density compared to the alveolar surface or direct intravenous access. While absorption through mucous membranes is generally faster than the oral route, it is significantly slower than the other options provided. Therefore, among the choices, it produces the **least (slowest) onset of action.** **Analysis of Incorrect Options:** * **D. Injection into blood vessels (Intravenous):** This provides the **fastest** onset of action because it bypasses the absorption phase entirely, achieving immediate 100% bioavailability. * **B. Inhalation of gaseous form:** This involves the **alveolar membrane**, which has a massive surface area (approx. 70-100 $m^2$) and an extremely rich capillary network. This results in an onset of action almost as rapid as an IV injection (e.g., volatile anesthetics). * **A. Application to a serous surface:** Serous membranes (like the peritoneum) have a very large surface area and high vascularity, leading to very rapid absorption, often faster than mucous membrane application. **NEET-PG High-Yield Pearls:** * **Order of Onset Speed:** IV > Inhalation (Alveolar) > Intraperitoneal/Serous > Intramuscular > Subcutaneous > Oral. * **Bioavailability:** Defined as the fraction of an unchanged drug that reaches the systemic circulation. It is 100% (1.0) for the IV route. * **First-Pass Metabolism:** Routes that bypass the liver (IV, Sublingual, Transdermal, Inhalation) have higher systemic availability compared to the oral route.

Q: What is the advantage of the sublingual route for drug administration?

It prevents or bypasses first-pass metabolism.. ### Explanation **Correct Option: A. It prevents or bypasses first-pass metabolism.** The sublingual route involves placing a drug under the tongue, where it dissolves and is absorbed directly through the oral mucosa into the systemic circulation via the **superior vena cava**. Unlike the oral route, the drug does not enter the portal circulation; therefore, it bypasses the liver (the primary site of first-pass metabolism). This ensures higher bioavailability and a rapid onset of action, making it ideal for emergencies like acute anginal attacks. **Analysis of Incorrect Options:** * **B. It is easy to administer:** While relatively simple, "ease of administration" is a subjective clinical convenience rather than a pharmacological advantage. The primary *pharmacokinetic* advantage is the bypass of hepatic metabolism. * **C. The drug must be lipid-soluble:** This is a **requirement** for the route to work, not an advantage. Only lipid-soluble, non-irritating drugs (e.g., Nitroglycerin, Buprenorphine) can diffuse across the lipid bilayer of the oral mucosa. * **D. It can be spit out if signs of toxicity appear:** While true that the drug can be removed to stop further absorption, this is a safety feature/precaution rather than the primary therapeutic advantage sought when choosing this route. **High-Yield Clinical Pearls for NEET-PG:** * **Nitroglycerin (GTN):** The classic example. It has very high first-pass metabolism (>90%), making the sublingual route essential for its efficacy in angina. * **Other Sublingual Drugs:** Buprenorphine (opioid), Desmopressin (analogue of ADH), and Nifedipine (though no longer preferred for hypertensive emergencies due to unpredictable BP drops). * **Key Concept:** Any drug absorbed from the mouth, pharynx, or rectum (partially) bypasses the liver, avoiding the "First-Pass Effect."

Q: Which of the following drugs is not converted into an active metabolite?

Lisinopril. **Explanation:** The question tests the concept of **Prodrugs** and **Active Metabolites**. Most drugs are inactivated by metabolism, but some are converted into active forms to exert their therapeutic effects. **Why Lisinopril is the Correct Answer:** Lisinopril is a notable exception among ACE inhibitors. While most ACE inhibitors (like Enalapril, Ramipril, and Perindopril) are **prodrugs** that must be converted by the liver into their active "-at" forms (e.g., Enalaprilat), **Lisinopril and Captopril are already active drugs**. They do not undergo hepatic activation and are excreted unchanged by the kidneys. This makes Lisinopril a preferred choice in patients with hepatic impairment. **Analysis of Incorrect Options:** * **Cyclophosphamide:** This is a classic **prodrug**. It is inactive in vitro and must be activated by hepatic cytochrome P450 enzymes into **4-hydroxycyclophosphamide** and **aldophosphamide** to exert its cytotoxic effect. * **Diazepam:** This benzodiazepine has a very long half-life because it is converted into several **active metabolites**, including **nordiazepam** (desmethyldiazepam) and **oxazepam**, which prolong its sedative effects. * **Fluoxetine:** This SSRI is metabolized into **norfluoxetine**, an active metabolite with an even longer half-life (7–15 days) than the parent drug, contributing to its sustained clinical effect. **NEET-PG High-Yield Pearls:** * **ACE Inhibitor Rule:** All ACE inhibitors are prodrugs **EXCEPT** Captopril and Lisinopril. * **Active Metabolite of Morphine:** Morphine-6-glucuronide (more potent than morphine). * **Prodrug of Epinephrine:** Dipivefrine (used in glaucoma). * **Prodrug of Dopamine:** Levodopa (crosses the blood-brain barrier).

Q: What is Hoffmann's elimination?

Inactivation of a drug by molecular rearrangement.. ### **Explanation** **Hoffmann's elimination** is a unique pharmacokinetic process where a drug undergoes spontaneous non-enzymatic degradation in the plasma and tissues. **1. Why Option D is Correct:** The correct answer is **inactivation of a drug by molecular rearrangement**. Unlike most drugs that require hepatic enzymes or renal clearance, drugs undergoing Hoffmann's elimination break down spontaneously due to the physiological pH and temperature of the body. This is a purely chemical process (molecular rearrangement) that does not involve any biological catalysts (enzymes). **2. Why Other Options are Incorrect:** * **Option A:** This refers to **biotransformation** (metabolism), typically occurring in the liver via Cytochrome P450 enzymes. * **Option B:** This refers to **renal excretion**, the primary route for water-soluble drugs. * **Option C:** This refers to **biliary or fecal excretion**, common for large molecular weight compounds or unabsorbed oral drugs. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Prototype Drug:** The classic example is **Atracurium** (a non-depolarizing neuromuscular blocker). Its derivative, **Cisatracurium**, also undergoes this process. * **Clinical Advantage:** Because it does not rely on the liver or kidneys, Atracurium is the **muscle relaxant of choice for patients with liver or kidney failure**. * **Factors Affecting Rate:** Since it is a chemical reaction, the rate of Hoffmann's elimination is increased by **hyperthermia** and **alkalosis**, and decreased by hypothermia and acidosis. * **Metabolite Note:** A byproduct of this reaction is **laudanosine**, which can cross the blood-brain barrier and potentially cause seizures in very high concentrations (though rare clinically).

Q: After three half-lives, what percentage of an original drug dose remains in the body?

12.50%. **Explanation** The concept of **Half-life ($t_{1/2}$)** refers to the time required for the plasma concentration of a drug to decrease by 50%. This follows **First-order kinetics**, where a constant fraction of the drug is eliminated per unit of time. To calculate the remaining percentage after multiple half-lives, we use the formula: **Remaining Amount = $100 \times (1/2)^n$** (where $n$ is the number of half-lives). * **Initial dose:** 100% * **After 1st half-life:** 50% remains * **After 2nd half-life:** 25% remains (50% of 50) * **After 3rd half-life:** **12.5% remains** (50% of 25) **Analysis of Options:** * **A (12.50%): Correct.** As calculated above, three half-lives reduce the drug concentration to one-eighth of the original dose. * **B (87.50%):** This represents the amount of drug **eliminated** after three half-lives (100% - 12.5%), not the amount remaining. * **C (75%):** This is the amount eliminated after two half-lives. * **D (94%):** This is the approximate amount eliminated after four half-lives (93.75%). **NEET-PG High-Yield Pearls:** 1. **Steady State:** It takes approximately **4 to 5 half-lives** for a drug to reach steady-state concentration ($C_{ss}$) during constant administration. 2. **Complete Elimination:** A drug is considered clinically "cleared" from the body after **5 half-lives** (97% eliminated). 3. **Zero-order Kinetics:** Unlike first-order, a constant *amount* (not fraction) is eliminated per unit time (e.g., Alcohol, Phenytoin, Aspirin at high doses). Here, half-life is not constant.

Question 1

Which of the following are examples of physiological antagonism?

Accepted Answer

Both B and C

Answer

Adrenaline and salbutamol

Answer

Adrenaline and histamine

Answer

Salbutamol and leukotrienes

Question 2

In competitive antagonism, what happens to the Vmax?

Accepted Answer

Vmax remains the same

Answer

Potency remains the same

Answer

Km decreases

Answer

Efficacy decreases

Question 3

Which route of administration will produce the least onset of action?

Accepted Answer

Application to a bronchotracheal mucous membrane

Answer

Application to a serous surface

Answer

Inhalation of gaseous form

Answer

Injection into blood vessels

Question 4

Receptor agonists possess which of the following properties?

Accepted Answer

Affinity and intrinsic activity

Answer

Affinity but no intrinsic activity

Answer

Intrinsic activity but no affinity

Answer

Affinity and intrinsic activity with a negative effect

Question 5

What is the advantage of the sublingual route for drug administration?

Accepted Answer

It prevents or bypasses first-pass metabolism.

Answer

It is easy to administer.

Answer

The drug must be lipid-soluble.

Answer

It can be spit out if signs of toxicity appear.

Question 6

Which of the following drugs exhibit zero-order kinetics at high doses?

Accepted Answer

Phenytoin and Propranolol

Answer

Digoxin and Propranolol

Answer

Amiloride and Probenecid

Answer

Lithium and Theophylline

Question 7

Which of the following drugs is not converted into an active metabolite?

Accepted Answer

Lisinopril

Answer

Cyclophosphamide

Answer

Diazepam

Answer

Fluoxetine

Question 8

Which one of the following drugs does not undergo the first-pass effect?

Accepted Answer

Insulin

Answer

Propranolol

Answer

Lidocaine

Answer

Morphine

Question 9

What is Hoffmann's elimination?

Accepted Answer

Inactivation of a drug by molecular rearrangement.

Answer

Inactivation of a drug by a metabolizing enzyme.

Answer

Unchanged excretion of a drug by the kidney.

Answer

Excretion of a drug in the feces.

Question 10

After three half-lives, what percentage of an original drug dose remains in the body?

Accepted Answer

12.50%

Answer

87.50%

Answer

75%

Answer

94%

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?